Identification of a prognostic signature based on expression of post-translational modification-related genes in acute myeloid leukemia.
This PTM-associated signature accurately stratifies AML patients and reveals immune microenvironment disparities, enabling precise personalized prognosis and identifies PTM-related genes as promising therapeutic targets for AML immunotherapy.